Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 24465050)

1.

The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus.

Wang H, Ni Y, Yang S, Li H, Li X, Feng B.

Curr Ther Res Clin Exp. 2013 Dec;75:88-92. doi: 10.1016/j.curtheres.2013.10.002.

2.

Treating newly diagnosed high blood pressure.

[No authors listed]

Am Fam Physician. 2015 Feb 1;91(3):Online. No abstract available.

PMID:
25822279
3.

Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin.

Aghili R, Malek M, Valojerdi AE, Banazadeh Z, Najafi L, Khamseh ME.

J Diabetes Metab Disord. 2014 Aug 21;13(1):88. doi: 10.1186/s40200-014-0088-z. eCollection 2014.

4.

MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients.

Wang G, Liu J, Yang N, Gao X, Fan H, Xu Y, Yang W.

PLoS One. 2014 Aug 22;9(8):e105698. doi: 10.1371/journal.pone.0105698. eCollection 2014.

5.

Case 2: Generalized swelling in a child with newly diagnosed diabetes mellitus.

Hursh BE, Dedhar A, Panagiotopoulos C.

Paediatr Child Health. 2014 May;19(5):233-4. No abstract available.

6.

Changes in adiponectin level and fat distribution in patients with type 2 diabetes.

Miazgowski T, Dziwura-Ogonowska J, Safranow K, Iskierska K, Widecka K.

Eur J Clin Invest. 2014 Feb;44(2):192-9. doi: 10.1111/eci.12207. Epub 2013 Dec 9.

PMID:
24251799
7.

[A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].

Shestakova MV, Suhareva OIu, Chernova TO, Shmushkovich IA, Aleksandrov AA, Il'in AV, Dedov II.

Ter Arkh. 2013;85(8):49-55. Russian.

PMID:
24137964
8.

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

Suzuki D, Toyoda M, Kimura M, Miyauchi M, Yamamoto N, Sato H, Tanaka E, Kuriyama Y, Miyatake H, Abe M, Umezono T, Fukagawa M.

Intern Med. 2013;52(10):1029-34. Epub 2013 May 15.

9.

Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.

Ji L, Li H, Guo X, Li Y, Hu R, Zhu Z.

PLoS One. 2013;8(2):e57222. doi: 10.1371/journal.pone.0057222. Epub 2013 Feb 28.

10.

The Effect of Early Intensive Insulin Therapy on Body Fat Distribution and β-Cell Function in Newly Diagnosed Type 2 Diabetes.

Son JW, Jeong HK, Lee SS, Kim SR, Cha BY, Son HY, Yoo SJ.

Endocr Res. 2013 Jan 3. [Epub ahead of print]

PMID:
23286324
12.

Pigment epithelium-derived factor increases in type 2 diabetes after treatment with metformin.

Akın S, Aksoy DY, Cınar N, Aydın K, Karaağaoğlu E, Arıyürek M, Gülçelik NE, Usman A, Gürlek A.

Clin Endocrinol (Oxf). 2012 Dec;77(6):852-6. doi: 10.1111/j.1365-2265.2012.04341.x.

PMID:
22248012
13.

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Bolinder J, Ljunggren Ö, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S.

J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31. doi: 10.1210/jc.2011-2260. Epub 2012 Jan 11.

PMID:
22238392
14.

Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.

Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, Tseng YH, Lin SY, Sheu WH.

Clin Ther. 2011 Dec;33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014. Epub 2011 Nov 10.

PMID:
22078152
15.

The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.

Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC.

J Diabetes Complications. 2011 Sep-Oct;25(5):332-8. doi: 10.1016/j.jdiacomp.2011.06.004. Epub 2011 Aug 2.

PMID:
21813293
16.

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.

Rodríguez A, Reviriego J, Karamanos V, del Cañizo FJ, Vlachogiannis N, Drossinos V; ECLA Study Group.

Cardiovasc Diabetol. 2011 Feb 11;10:18. doi: 10.1186/1475-2840-10-18.

17.

Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.

Esposito K, Maiorino MI, Di Palo C, Gicchino M, Petrizzo M, Bellastella G, Saccomanno F, Giugliano D.

Diabetes Obes Metab. 2011 May;13(5):439-45. doi: 10.1111/j.1463-1326.2011.01367.x. Epub 2011 Jan 21.

PMID:
21255215
18.
19.

Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.

Kadoglou NP, Kapelouzou A, Tsanikidis H, Vitta I, Liapis CD, Sailer N.

Exp Clin Endocrinol Diabetes. 2011 Feb;119(2):63-8. doi: 10.1055/s-0030-1265174. Epub 2010 Oct 28.

PMID:
21031343
20.

Vildagliptin: a review of its use in type 2 diabetes mellitus.

Keating GM.

Drugs. 2010 Nov 12;70(16):2089-112. doi: 10.2165/11206370-000000000-00000. Review.

PMID:
20964454
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk